Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 2)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/26276
• EU PAS number:
  EUPAS10923
• Study ID:
  26276
• Official title and acronym:
  Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 2)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 2):− Compare the effectiveness (in terms of moderate and severe exacerbation prevention) of prescribing inhaler devices with similar inhalation techniques vs prescribing devices with dissimilar inhalation techniques in patients with COPD − Assess therapy adherence in patients with COPD prescribed inhaler devices with similar inhalation techniques vs patients prescribed devices with dissimilar inhalation techniques
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 18/06/2015

Actual: 08/04/2016

Study start date

Planned: 28/08/2015

Actual: 28/08/2015

Data analysis start date

Planned: 14/09/2015

Date of interim report, if expected

Planned: 25/01/2016

Date of final study report

Planned: 08/02/2016

Actual: 08/04/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Teva

Study protocol

Initial protocol

DASG study similar vs dissimilar devices COPD Phase 2_Protocol_AJ

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable